Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with
Gilles Salles, University of Lyon
Patients in the PRIMA study who had achieved remissions for their follicular lymphoma by means of immunochemotherapy had only half the risk of recurrence if they also received maintenance therapy with rituximab for two years compared with those who did not. Gilles Salles from the University of Lyon discussed his findings with Peter Goodwin during the 2010 European Hematology Association annual congress in Barcelona.
LISTEN
[audio:https://www.audiomedica.com/podcasting/otbn/100611GillesSallesPodcastOTBN.mp3]
Related Episodes
Multiple Myeloma: Big Survival Gains From Novel Agents In The Real World
Big improvements in survival among patients with multiple myeloma were reported at the European Hematology Association annual congress in Barcelona by Greek researchers looking at the past decade of t